Reported about 12 hours ago
This article evaluates Jim Cramer's perspective on Pfizer Inc. (PFE), a pharmaceutical company facing challenges post-COVID. Despite recommending patience due to Pfizer's acquisition of Seagen and its yield, PFE's stock has declined by over 20%. Cramer remains optimistic about the potential of the Seagen deal, yet the article suggests that other AI stocks may offer better investment prospects.
Source: YAHOO